Beta-Glucans for Gut Health

Research suggests that beta-glucans, particularly those derived from fungal sources such as Aureobasidium pullulans and yeast, may exert prebiotic-like effects on the gut microbiome, with several small studies reporting shifts toward bacteria associated with gut health — including Bifidobacterium, Lactobacillus, Faecalibacterium prausnitzii, and butyrate-producing species — alongside reductions in inflammation-linked genera. Studies indicate that these microbial changes are accompanied by alterations in short-chain fatty acid production and gut metabolite profiles, and one mouse study found that the gut microbiome itself appears necessary for beta-glucan's protective effects against chemically induced colitis, since antibiotic-mediated depletion of gut bacteria abolished those benefits. The available evidence comes predominantly from small pilot studies and animal models — including studies in patients with multiple sclerosis, Duchenne muscular dystrophy, and NASH — with very few randomized controlled trials, no large-scale human trials, and no control groups in several cases, which substantially limits the conclusions that can be drawn. While the directional findings are generally consistent and encouraging, the field remains in early stages, and larger, well-controlled human trials are needed before the gut health effects of beta-glucans can be considered established.